Publication | Open Access

Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

Survival OutcomesOncologyBreast OncologyMedicineNeoadjuvant LetrozoleGynecologyBreast CancerPharmacotherapyCancer TreatmentPharmacologyRadiation Oncology